NO950634L - New glucan preparation - Google Patents

New glucan preparation

Info

Publication number
NO950634L
NO950634L NO950634A NO950634A NO950634L NO 950634 L NO950634 L NO 950634L NO 950634 A NO950634 A NO 950634A NO 950634 A NO950634 A NO 950634A NO 950634 L NO950634 L NO 950634L
Authority
NO
Norway
Prior art keywords
neutral
production
glucan
glucans
aqueous
Prior art date
Application number
NO950634A
Other languages
Norwegian (no)
Other versions
NO950634D0 (en
Inventor
Spiros Jamas
Jr D Davidson Easson
Gary R Ostroff
Original Assignee
Alpha Beta Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/934,015 external-priority patent/US5622939A/en
Application filed by Alpha Beta Technology filed Critical Alpha Beta Technology
Publication of NO950634D0 publication Critical patent/NO950634D0/en
Publication of NO950634L publication Critical patent/NO950634L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Den foreliggende oppfinnelse vedører nøytrale, vandige leselige /3-glukaner som har potente og spesifikke immunolo- giske effekter uten å stimulere produksjonen av visse cyto- kiner, preparater som inneholder de nye /3-glukaner, og en ny fremstillingsfremgangsmåte for disse. Det noytrale, vandige løselige /3-glukanpreparat har høy affinitet for 0-glukan- reseptoren på humane monocytter, og beholder to primære biolo- giske (eller immunologiske) aktiviteter, (1) økningen av mikrobicid aktivitet hos fagocyttceller, og (2) monocytt, neutrofil og blodplatehemopoietisk aktivitet. Ulikt løselige glukaner beskrevet i tidligere teknologi, vil det nøytrale, vandige løselige /3-glukan ifølge denne oppfinnelse verken indusere eller prime IL-1/3 og TNFa-produksjon in vitro og in vivo. Sikre og virksomme preparater av nøytralt, vandig løselige /3-glukan ifølge den foreliggende oppfinnelse kan anvendes i terapeutiske og/eller profylaktiske behandlings- regimer av mennesker og dyr for å øke deres immunrespons, uten å stimulere produksjonen av visse biokjemiske mediatorer (f.eks. IL-1/3, TNFa) som kan forårsake skadelige side- virkninger, slik som feber og betennelse.The present invention relates to neutral, aqueous readable β-glucans that have potent and specific immunological effects without stimulating the production of certain cytokines, preparations containing the novel β-glucans, and a novel process for their production. The neutral, aqueous soluble / 3-glucan preparation has high affinity for the 0-glucan receptor on human monocytes, and retains two primary biological (or immunological) activities, (1) the increase of microbicidal activity in phagocyte cells, and (2) monocyte , neutrophil and platelet hemopoietic activity. Unlike soluble glucans described in the prior art, the neutral aqueous soluble β-glucan of this invention will neither induce nor prime IL-1/3 and TNFα production in vitro and in vivo. Safe and effective preparations of neutral, aqueous soluble β-glucan of the present invention can be used in therapeutic and / or prophylactic treatment regimens of humans and animals to enhance their immune response, without stimulating the production of certain biochemical mediators (e.g. IL-1/3, TNFα) which can cause harmful side effects, such as fever and inflammation.

NO950634A 1992-08-21 1995-02-20 New glucan preparation NO950634L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/934,015 US5622939A (en) 1992-08-21 1992-08-21 Glucan preparation
PCT/US1993/007904 WO1994004163A1 (en) 1992-08-21 1993-08-20 Novel glucan preparation

Publications (2)

Publication Number Publication Date
NO950634D0 NO950634D0 (en) 1995-02-20
NO950634L true NO950634L (en) 1995-04-20

Family

ID=26786977

Family Applications (1)

Application Number Title Priority Date Filing Date
NO950634A NO950634L (en) 1992-08-21 1995-02-20 New glucan preparation

Country Status (2)

Country Link
CA (1) CA2142811C (en)
NO (1) NO950634L (en)

Also Published As

Publication number Publication date
NO950634D0 (en) 1995-02-20
CA2142811C (en) 2006-10-31
CA2142811A1 (en) 1994-03-03

Similar Documents

Publication Publication Date Title
FI950770A (en) New glucan preparation
Seljelid et al. Glycan stimulation of macrophages in vitro
BR8803442A (en) POLYSACARIDE, PROCESS FOR THE PREPARATION OF POLYSACARIDES, MEDICINE FOR HUMAN OR ANIMAL USE AND FOOD ADDITIVE
ES2211943T3 (en) THERAPEUTIC USES OF GLUCANO.
CA2354832A1 (en) Chlorella preparations exhibiting immunomodulating properties
DK66692D0 (en) A MAMMAL CYTOKIN, IL-11
Bouissil et al. Applications of algal polysaccharides and derivatives in therapeutic and agricultural fields
SK342004A3 (en) Method for the preparation of glucan hydrogel having antibacterial and immunostimulant activity and its use
ES2082749T3 (en) SYNERGIC INTERACTION OF INTERLEUKIN-2 AND DOUBLE CHAIN RNA.
NO950634L (en) New glucan preparation
SE8502553D0 (en) STABLE COMPOSITIONS
Raftos et al. Invertebrate cytokines II: release of interleukin-1-like molecules from tunicate hemocytes stimulated with zymosan
DE69824358D1 (en) LALF peptide fragment with antiviral activity
ATE99310T1 (en) SUBSTITUTED 1,8-NAPHTHYRIDINE.
HU9201197D0 (en) Protection from shock subsequent to injury by double-stranded rns
ATE52687T1 (en) HAIR TREATMENTS.
ES8302460A1 (en) Method for the production of an antithrombin-heparin complex and pharmaceutical compositions containing the complex.
JPS646209A (en) Hair cosmetic
GB2181351A (en) Disinfectant compositions
DK0831722T3 (en) Gel system which includes carrageenan and coconut endosperm
PEŠTALIĆ et al. Influence of Age and Education of Patients on Prevalence Giardia lamblia in Human
SU1022361A1 (en) Method of capsule antigen preparing
Magrill The effect of phytate concentration of ph and of orthophosphate on the rate of phytate adsorption by hydroxyapatite
KR960006930A (en) How to improve human immune system and treat human disease using kiwi
范少光 et al. Suppressive effect of stress on the release of hydrogen peroxide from rat macrophages